IDRA - Idera Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6000
-0.0300 (-1.84%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.6300
Open1.6500
Bid1.5900 x 1400
Ask1.6500 x 1800
Day's Range1.5900 - 1.6800
52 Week Range1.5500 - 4.2600
Volume165,719
Avg. Volume131,480
Market Cap46M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    EXTON, Pa., Nov. 06, 2019 -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the.

  • GlobeNewswire

    Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037

    Idera Pharmaceuticals, Inc. (IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No. 10,10,463,686 entitled “Immune Modulation With TLR9 Agonists For Cancer Treatment,” which includes the Company’s investigational therapy tilsotolimod (IMO-2125). Idera also continues to focus on the acquisition, development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

  • GlobeNewswire

    Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

    Idera Pharmaceuticals, Inc. (IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9) agonist, in combination with nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody for the treatment of solid tumors. To learn more about Idera, visit www.iderapharma.com.

  • GlobeNewswire

    Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie

    Idera Pharmaceuticals, Inc. (IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company.  The purpose of the collaboration is to conduct a clinical study evaluating whether combinations of an OX40 agonist (ABBV-368), a TLR-9 agonist (tilsotolimod), chemotherapy (nab-paclitaxel) and/or an anti-programmed cell death 1 (PD-1) antagonist (ABBV-181) stimulate the immune system resulting in anti-tumor responses. Under the terms of the agreement, Idera will provide clinical trial supply of tilsotolimod to AbbVie and AbbVie will be responsible for conduct of the study.

  • GlobeNewswire

    Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference

    EXTON, Pa., Aug. 30, 2019 -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on.

  • GlobeNewswire

    Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results

    EXTON, Pa., Aug. 08, 2019 -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the.

  • GlobeNewswire

    Idera to Release 2019 Second Quarter Results on August 8, 2019

    Idera Pharmaceuticals, Inc. (“Idera”) (IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today announced that second quarter results for 2019 are expected to be released on Thursday, August 8, 2019 before the opening of the U.S. financial markets. The company will host a conference call and live audio webcast at 10:00 A.M. eastern time on the same day.  During the conference call, Idera management will also provide a corporate update along with a question and answer session.

  • GlobeNewswire

    Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer

    Idera Pharmaceuticals, Inc. (IDRA) today announced the appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and the promotion of John J. Kirby to Chief Financial Officer. Dr. Tarka was most recently the Vice President of Clinical Development at Complexa, Incorporated. Mr. Kirby has led Idera’s finance department as Principal Financial Officer and Principal Accounting Officer since October 2018.

  • GlobeNewswire

    Idera Pharmaceuticals to Present at the 2019 JMP Securities Life Sciences Conference

    Harnessing the approach of the earliest researchers in immunotherapy and the Company’s vast experience in developing proprietary immunology platforms, Idera’s lead development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs. To learn more about Idera, visit www.iderapharma.com.

  • GlobeNewswire

    Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

    EXTON, Pa., May 02, 2019 -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the.

  • GlobeNewswire

    Idera Pharmaceuticals Provides Corporate Update

    Idera Pharmaceuticals, Inc. (“Idera”) (IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today announced that Cristina Csimma, Pharm. D., M.H.P. and Michael Dougherty have been appointed to the Board of Directors, effective April 10, 2019.

  • GlobeNewswire

    Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting

    Idera Pharmaceuticals, Inc. (“Idera”) (IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today is reporting clinical and translational data from the ILLUMINATE-101 Phase 1 study which explored the role of investigational tilsotolimod as monotherapy in patients with various refractory solid tumors. In the poster presentation entitled, “Activation of Innate and Adaptive Immunity Using Intratumoral Tilsotolimod (IMO-2125) as Monotherapy in Patients with Refractory Solid Tumors: a Phase 1b Study (ILLUMINATE-101)” (abstract number 4062), Hani Babiker, M.D., Assistant Professor of Medicine and Associate Director of the Phase 1 Program at the University of Arizona Cancer Center, presented results from this study.

  • GlobeNewswire

    Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

    – ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 –– ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 –– ILLUMINATE-206 Trial Expected to Initiate Q2 2019.

  • GlobeNewswire

    Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

    Idera Pharmaceuticals, Inc. (IDRA) today announced completion of enrollment into the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*) in patients with unresectable or metastatic melanoma following failure of PD-1 inhibitor treatment. 52 patients have been dosed in the trial which included two separate patient groups.  The company completed the targeted enrollment of 40 patients in the primary enrollment population, constituting patients who are naïve to prior ipilimumab treatment in the metastatic setting.  This patient population mirrors the enrollment for the ILLUMINATE-301 phase 3 pivotal trial.  The secondary exploratory enrollment population targeted up to 20 patients who had prior ipilimumab treatment in the metastatic setting.

  • GlobeNewswire

    Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Idera Pharmaceuticals, Inc. (IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. An archived version will also be available on the company’s website after the event for 90 days. As a convenience to investors, a copy of the company’s presentation will be posted on the Idera corporate website at 7:30 a.m. Eastern Time on Monday, January 7, 2019.

  • GlobeNewswire

    Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors

    Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking and equity capital markets, as well as corporate finance and business development in the biopharmaceutical sector.  Ms. Schafer most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities.  Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals.  Earlier in her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as a Managing Director at J.P. Morgan.  Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University. “Carol brings a unique set of skills and experience that traverses the financial and corporate biotech landscape and will be incredibly valuable to our board as we continue to advance Idera’s mission to bring forward options for patients suffering from life-threatening diseases and ultimately create long-term shareholder value,” stated James Geraghty, Chairman of Idera’s Board of Directors.

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: Johnson & Johnson and Idera Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Both Johnson & Johnson and Idera Pharmaceuticals were big losers in Friday’s trading session. J&J tumbled on a Reuters story that alleged it knew about its baby powder having asbestos for decades while Idera announced data from an ongoing phase 2 trial that were actually encouraging. Johnson & Johnson shares were tanking on Friday, on a Retuers story that the company had known for decades that its baby powder has asbestos.

  • GlobeNewswire

    Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

    Idera Pharmaceuticals, Inc. (IDRA) today is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*).